SpectronRx

Great perspective in AJMC - The American Journal of Managed Care from Tyler Middlebrooks, MS on the growing value of Radioligand Therapy in community oncology.

As the field advances, expanding access matters just as much as innovation itself. Patients should not have to travel long distances to receive leading-edge care. Bringing advanced therapies closer to home can improve convenience, continuity and the overall treatment experience for patients and families.

At SpectronRx, we believe the future of radiopharmaceuticals depends on the infrastructure that helps make access possible, from isotope supply to reliable manufacturing and delivery in a time-sensitive, decay-driven environment.

Community oncology will play an increasingly important role in helping more patients benefit from the next generation of precision medicine.

👉 Learn more here: https://www.ajmc.com/view/the-value-of-radioligand-therapy-in-community-oncology-world-class-care-close-to-home

Proud to support Plus Therapeutics, Inc. as they advance late-stage clinical manufacturing for Rhenium-186 and REYOBIQ.

This milestone reflects the importance of building resilient, scalable supply chain infrastructure across radiopharmaceutical development. In a time-sensitive, decay-driven environment, reliable manufacturing capacity and trusted ex*****on matter.

With SpectronRx serving as an additional GMP manufacturing site, this collaboration underscores how strong partnerships help move promising therapies closer to patients. We appreciate the opportunity to support this important program and look forward to the road ahead.

👉 Read more here: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-initiates-manufacturing-activities-spectronrx